# The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

> **NCT05438797** · EARLY_PHASE1 · UNKNOWN · sponsor: **Sizhen Wang** · enrollment: 3 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Adoptive TIL-TCM transfer therapy

## Key facts

- **NCT ID:** NCT05438797
- **Lead sponsor:** Sizhen Wang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-02
- **Primary completion:** 2024-04
- **Final completion:** 2024-04
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438797, "The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05438797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*